Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Fineline Cube Apr 27, 2026
Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Fineline Cube Apr 27, 2026
Company Deals

Zhaoke Ophthalmology Partners with Jamjoom Pharma for Cyclosporine Eye Gel Distribution in Middle East

Fineline Cube Jul 1, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) announced a partnership with Jamjoom Pharma, a leading Saudi...

Company Drug

Ascletis Faces Patent Challenge from CSPC Subsidiary Conjupro Bio

Fineline Cube Jul 1, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) this week disclosed that Conjupro Biotherapeutics, a subsidiary of...

Company Deals

Fosun Pharma Secures Licensing Deal for HCB101 SIRPα-Fc Fusion Protein

Fineline Cube Jul 1, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) has entered into a licensing...

Company Drug

Zai Lab’s Bemarituzumab Meets Phase III Endpoint in Gastric Cancer Trial

Fineline Cube Jul 1, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that its Phase III FORTITUDE-101...

Company Drug

Hengrui Pharmaceuticals’ Aihengping Gains NMPA Approval for Regional Analgesia

Fineline Cube Jul 1, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received marketing approval...

Company Drug

Avistone’s Vebreltinib Wins NMPA Approval for MET-Amplified NSCLC

Fineline Cube Jul 1, 2025

Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd. announced that its subsidiary Pearl Bio’s c-MET inhibitor vebreltinib...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Approval for Aisuda in Severe Alopecia Areata

Fineline Cube Jul 1, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has received additional indication approval from the...

Company Medical Device

MicroPort NeuroTech’s NUMEN Nest Gains FDA Marketing Approval

Fineline Cube Jul 1, 2025

China-based MicroPort NeuroTech Limited (HKG: 2172) announced that its NUMEN Nest, an enhanced version of...

Company Drug

BMS Secures FDA Approval for Updated Labels of Breyanzi and Abecma

Fineline Cube Jul 1, 2025

US major Bristol-Myers Squibb (BMS; NYSE: BMY) announced that the US Food and Drug Administration...

Company Deals

GenScript Receives $213.8M Payment from LaNova for PD-1 Antibody License

Fineline Cube Jun 30, 2025

China-based GenScript Biotech Corporation (HKG: 1548) announced that it has received a payment of USD...

Company Drug

UCB’s Fenfluramine Shows Positive Results in Phase III GEMZ Study for CDKL5 Deficiency Disorder

Fineline Cube Jun 30, 2025

Belgium-based biopharma UCB (EBR: UCB) announced positive results from its Phase III GEMZ study, evaluating...

Company Deals

Sunshine Lake Pharma Lists on HKEX via Introduction Method

Fineline Cube Jun 30, 2025

China-based Sunshine Lake Pharma Co., Ltd. (HKG: 6887) has successfully listed on the Main Board...

Company Deals

MGI Tech Partners with Italy’s Negedia to Advance Genomic Sequencing and Spatial Transcriptomics

Fineline Cube Jun 30, 2025

China-based gene sequencing specialist MGI Tech Co., Ltd. announced a collaboration with Italy’s Negedia to...

Policy / Regulatory

China Proposes Healthcare Security Law to Strengthen Medical Insurance System

Fineline Cube Jun 30, 2025

China’s National Healthcare Security Administration (NHSA) last week released the “Healthcare Security Law (draft proposal)”,...

Company Deals

QuantumPharm and Pfizer Expand Collaboration on Advanced Molecular Simulation Platform

Fineline Cube Jun 30, 2025

Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228), has announced an expansion of its...

Company Deals

BlissBio Inc. Files for Hong Kong IPO to Advance Oncology-Focused ADC Pipeline

Fineline Cube Jun 30, 2025

Hangzhou-based oncology-focused clinical-stage biotech BlissBio Inc. has filed for an initial public offering (IPO) with...

Policy / Regulatory

FDA Removes REMS Requirements for BCMA- and CD19-Targeted CAR-T Therapies

Fineline Cube Jun 30, 2025

The U.S. Food and Drug Administration (FDA) last week announced the removal of Risk Evaluation...

Company Deals

ProFound Therapeutics and Novartis Forge Four-Year Partnership for Cardiovascular Drug Targets

Fineline Cube Jun 30, 2025

US-based ProFound Therapeutics announced a four-year partnership with Swiss giant Novartis (NYSE: NVS) to discover...

Company Deals

Diagens Biotech’s AI Imaging Platform iMedImage Makes Hong Kong IPO Debut

Fineline Cube Jun 30, 2025

China-based Hangzhou Diagens Biotechnology Co., Ltd. has filed for an initial public offering (IPO) with...

Company Drug

Pfizer’s Emblaveo Approved by China’s NMPA for Complex Infections

Fineline Cube Jun 30, 2025

US giant Pfizer Inc., (NYSE: PFE) announced that it has received marketing approval from China’s...

Posts pagination

1 … 126 127 128 … 657

Recent updates

  • Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU
  • Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104
  • Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B
  • CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers
  • Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Company Drug

Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B

Company Drug

CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.